Contract valued at $1.4 million allows for the use of SoftFocus products and access to medicinal chemistry services.

Galapagos’ service division BioFocus will receive Euro 1.1 million ($1.4 million) as the result of a one-year extension of its agreement with Merck Serono. BioFocus will provide SoftFocus compounds for use in Merck Serono’s drug discovery programs. In a separate agreement, BioFocus will continue to perform medicinal chemistry services on an undisclosed Merck Serono program.

In 2005, Galapagos’ BioFocus inked an agreement with Merck Serono to supply biologically directed library compounds from its SoftFocus collection throughout 2005–2006. According to the companies, BioFocus’ medicinal chemistry services accelerated Merck Serono’s existing drug discovery programs.

Previous articleProtein Found that Causes Autophagy in Ovarian Cancer Cells
Next articleGenzyme and ICGEB Join Forces to Advance Malaria Treatments